<< Exhibitor
<< Press release
The 22nd China International In Vitro Diagnostics Expo by CACLP and the 5th China IVD Supply Chain Expo (CISCE) took place from 22–24 March 2025 in Hangzhou, achieving unprecedented scale and impact.
With just two weeks to go, anticipation is building for the 22nd China International In Vitro Diagnostic Expo by CACLP, the largest and most influential gathering of the IVD industry in China! Taking place 22-24 March 2025, at the Hangzhou Grand Convention & Exhibition Center, CACLP 2025 promises to be a world-class showcase of the latest innovations, professional networking and business opportunities.
The 7th China IVD Distribution Enterprise Forum is set to take place on 23 March 2025, at the Hangzhou Grand Convention and Exhibition Center.
As China’s in vitro diagnostic (IVD) industry continues its rapid development, numerous outstanding enterprises have made remarkable achievements in research and development, production, and market expansion.
Welcome to the 22nd China International In Vitro Diagnostic Expo by CACLP & 5th China IVD Supply Chain Expo!
The 1st National Primary Healthcare Laboratory Forum is a key event focused on strengthening primary healthcare laboratory testing, which plays a vital role in early disease diagnosis and treatment outcomes.
As China’s pet market continues to flourish, with rising pet ownership and increasing per capita spending, the demand for quality veterinary care is rapidly growing.
The 10th China Experimental Medicine Conference is set to take place on 21-23 March 2025, at the Hangzhou Grand Convention and Exhibition Center.
The 5th China Key Raw Material & Parts Forum is set to take place on 21 March 2025, at the Hangzhou Grand Convention and Exhibition Center.
The 12th China IVD Industry Development Conference is set to take place on 22-23 March 2025, at the Hangzhou Grand Convention and Exhibition Center.
<< Industry news
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the first quarter ended March 31, 2025.
Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the first quarter of fiscal year 2025.
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025.
Siemens Healthineers AG today announces its results for the second quarter of fiscal year 2025 ended March 31, 2025.
As of April 30, 2025, there are 82 publicly listed companies in China engaged in the in vitro diagnostics (IVD) industry. Among them, 61 companies focus primarily on IVD, while 21 have IVD as part of their broader business portfolios.
Diasorin said Tuesday that the firm's first quarter revenues jumped 8 percent year over year with growth across the company's immunodiagnostics, molecular diagnostics, and licensed technologies businesses.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2025 second quarter, which ended March 31, 2025.
In 2024, China’s IVD market size is expected to be less than RMB 120 billion, remaining flat compared to 2023. Domestic brands account for approximately 50% of the market.
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire Capsulomics, Inc., d/b/a Previse. Previse is a gastrointestinal health company with a primary focus on chronic acid reflux related diseases, including esophageal cancer. The terms of the agreement are undisclosed.
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, has entered into an agreement with Incyte Diagnostics to acquire select assets of its clinical testing business, including multiple same-day testing day labs, and select technical assets of Incyte Diagnostics’ anatomic pathology (AP) business including Incyte’s main AP laboratory in Spokane, Washington, and its labs in Tukwila and Richland, Washington, and Missoula, Montana.
<< Video showcase
CACLP 2025 onsite - The Convergence of Laboratory Medicine and In Vitro Diagnostics
The 12th China IVD Industry Development Conference (CIIDC)
The 10th China Experimental Medicine Conference (CEMC)
International Laboratory Medicine and In Vitro Diagnostic Forum
The 11th China IVD Industry Development Conference (CIIDC)
The 9th China Experimental Medicine Conference (CEMC)
CACLP 2024 onsite - The Convergence of Laboratory Medicine and In Vitro Diagnostics
CACLP APP is available for download now!
Gentian at CACLP 2023 Onsite
in.vent Diagnostics at CACLP 2023 Onsite
Charming Group at CACLP 2023 Onsite
Dialab at CACLP 2023 Onsite
JTC at CACLP 2023 Onsite
Certest at CACLP 2023 Onsite
Yashraj Biotechnology at CACLP 2023 Onsite
Magtivio at CACLP 2023 Onsite
The 8th China Experimental Medicine Conference (CEMC)
The 10th China IVD Industry Development Conference (CIIDC)
CACLP 2023 onsite - The Convergence of Laboratory Medicine and In Vitro Diagnostics
CACLP's new website is launching!
<< Download centre
CACLP 2025 Post-show Press Release
CACLP 2025 Exhibitor Manual
CACLP 2025 Floor Plan
CACLP 2025 Full Schedule
CACLP & CISCE 2024 Draw Global Attention to Innovations and Collaborations in IVD Industry
CACLP & CISCE to present the latest in IVD with 1300+ Exhibitors and 100+ Concurrent Activities this March in Chongqing.pdf
CACLP & CISCE 2024 - Floor Plan
CACLP & CISCE 2024 - Exhibitor Manual
1200+ Global Exhibitors Confirmed Their Participation on the 21st CACLP and 4th CISCE in Chongqing, March 2024
CACLP & CISCE 2023 Post-show Report
Copyright © 2025 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.
Go back
